Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data. - Wikidata - wikimedia - TriplyDB

Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.

Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.

http://www.wikidata.org/entity/Q33685903

about

Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse

P2860

Q39452113-DBD57660-031F-45F6-9186-39CEF62FDBFC

P2860

Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.

http://www.wikidata.org/entity/Q33685903

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.

@ast

Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.

@en

type

label

Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.

@ast

Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.

@en

prefLabel

Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.

@ast

Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.

@en

P1433

Q33685903-AC400290-0AF3-4602-A1B5-114916843E10

P1476

Q33685903-2BD81046-B8D1-4561-9E48-5C4A211052D5

P2093

Q33685903-D501CCF8-DD60-4F44-B2C4-D728DC24CDC4

P2860

Q33685903-0A622AF5-9F87-4E62-B671-811E24E38A7F

Q33685903-1C7FEDE5-A758-4E79-BDDA-AFD28F6A45A5

Q33685903-1F4D4C9C-A25B-47B7-8673-61E4F807AB21

Q33685903-21FFD6D8-D2B9-4616-91A2-D2854528F7DD

Q33685903-23245E1D-EE8B-4442-8846-1635A356A26B

Q33685903-33D50489-7497-48BB-ADFA-C89DEEF7C1C4

Q33685903-41183BFA-619C-4534-94E7-1F51A9A90B06

Q33685903-426D74A6-4390-43AC-894D-BB7042D464AA

Q33685903-4B9EDE69-0F20-4765-95E2-52CB30017DDD

Q33685903-501A5B7D-4953-4A3F-9B6A-46A66368B944

P2888

Q33685903-8AF0A45B-617B-4F0C-9C87-CBBC9486738D

P304

Q33685903-E09AECA9-7477-434F-9776-BB3B9D851ABE

P31

Q33685903-1FBFB969-1CAB-45AF-91AC-3AA3F11174F0

P356

Q33685903-15065382-8B9D-419C-9AB0-5EE62323A7F0

P433

Q33685903-4B978B37-3062-4D38-9A3A-FEF1FCCF6FA5

P478

Q33685903-EB5EE28F-BBD4-4851-BE7A-90C4E2F9C04F

P577

Q33685903-60BA0AAC-DCDD-4F46-93E2-B84A43F2D867

P6179

Q33685903-FCCE2B37-72F0-4847-9FCE-C5C1E8A38A7C

P698

Q33685903-041541FA-EE77-46E9-9792-DB3510DFF5D8

P356

S11912-010-0128-X

P1433

Current Oncology Reports

P1476

Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.

@en

P2093

Fredrick B Hagemeister

http://www.w3.org/2001/XMLSchema#string

P2860

Rapamycins: mechanism of action and cellular resistance

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma.

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

P2888

s11912-010-0128-x

P304

395-401

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-010-0128-X

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1045927619

http://www.w3.org/2001/XMLSchema#string

P698

20820960

http://www.w3.org/2001/XMLSchema#string